Milatuzumab-doxorubicin conjugate

Drug Profile

Milatuzumab-doxorubicin conjugate

Alternative Names: CD-74-DOX; hCD74-DOX; hLL1-DOX; IMMU-110; Milatuzumab-DOX

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Feb 2016 No development reported - Phase-I/II for Chronic lymphocytic leukaemia (Recurrent, Second-line therapy or greater) in USA (IV)
  • 25 Feb 2016 No development reported - Phase-I/II for Multiple myeloma (Recurrent) in USA (IV)
  • 25 Feb 2016 No development reported - Phase-I/II for Non-Hodgkin's lymphoma (Recurrent, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top